RT Journal Article
SR Electronic
T1 The Endothelial Dysfunction and Pyroptosis Driving the SARS-CoV-2 Immune-Thrombosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.17.20133124
DO 10.1101/2020.06.17.20133124
A1 Nagashima, Seigo
A1 Mendes, Monalisa C.
A1 Martins, Ana Paula C.
A1 Borges, Nicolas H.
A1 Godoy, Thiago M.
A1 Ribeiro, Anna Flavia M.
A1 Dezidério, Felipe S.
A1 de Noronha, Lucia
A1 Machado-Souza, Cleber
YR 2020
UL http://medrxiv.org/content/early/2020/06/19/2020.06.17.20133124.abstract
AB Objective Endothelial activation after viral infection could contribute to changes in the vascular glycocalyx associated with programmed inflammatory cell death called pyroptosis. Thus, our goal is to recognize endothelial activation and pyroptosis in lung and myocardial samples of Coronavirus disease (COVID-19) cases and compare to H1N1pdm09 and control cases.Approach and Results Post-mortem lung (6 cases of COVID-19 group; 10 cases of H1N1 group and 11 cases of Control group) and myocardial samples (2 cases of COVID-19 and one control) were analyzed by conventional immunohistochemistry by using antibodies to identify molecules involving with endothelial activation (CD163, Interleukin-6 (IL-6), Tumor Necrosis Factor alpha (TNF-alpha), Intercellular Adhesion Molecule 1 (ICAM-1)) and pyroptosis (Caspase-1). As a result, IL-6, TNF-alpha, ICAM-1, and Caspase-1 show higher tissue expression in the COVID-19 group compared to H1N1 and Control groups.Conclusion Our results indicate that the vascular endothelium has been activated and the presence of pyroptosis and endothelial dysfunction in lung and myocardial samples. These conditions could lead to a systemic immune-thrombotic process that may impair the clinical staff’s efforts to prevent fatal outcomes. One aim of the health professionals is to avoid COVID-19 systemic vascular injury and immune-thrombosis by blocking the endothelial dysfunction and its consequences.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The presented study was approved by the National Research Ethics Committee (Conselho Nacional de Ética em Pesquisa CONEP), protocol number 3.944.734/2020, and 2.550.445/2018. The authors to confirm that all methods were carried out in accordance with relevant guidelines and regulations. Families permitted the postmortem biopsy of the cases of COVID19 and H1N1pdm09.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that all data referred in the manuscript are available.